Gennex Laboratories Limited is an integrated pharmaceutical company and has a product portfolio spread over various product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The Company is engaged in manufacturing of bulk drugs, intermediates and biotech products. It operates through Pharmaceutical Products segment. Its products include active pharmaceutical ingredients (APIs), such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Metformin Hcl IP/BP, which is an anti-diabetic product; Ambroxol Hcl IP/BP, which is an expectorant, (mucolyte), and Melitracen Hcl, which is an antidepressant and anxiolytic. The Company intends to offers other APIs, such as Flupentixol DIHCL BP, Domperidone BP/EP, Mephenesin BP, Mefanemic Acid USP/BP/IP and Chlorophenesin USP/BP.